Close menu




May 6th, 2021 | 05:17 CEST

Volkswagen, Deutsche Bank, QMines: These trends are developing now!

  • Investments
Photo credits: olivecapital.com.au

The financial scene is currently dominated by two issues: The impact of technological change and changes in the wake of the pandemic and rising inflation. The first set of issues has pushed the markets for many years. Rising inflation has only recently become an issue. The economy held steady during the second and third waves and continued to grow slowly. At the same time, the anticipation of openings is growing. This explosive mix has already caused some commodity prices to rise. The market themes of technological change and inflation are cumulating in the price of copper, which has been rising dynamically for months, benefiting from both the e-car boom and the strengthening economy. We present three companies that could become trending stocks - and one of them went pubic today.

time to read: 3 minutes | Author: Nico Popp
ISIN: DE0007664039 , DE0005140008 , AU0000141533

Table of contents:


    Volkswagen: The new Tesla?

    German automaker Volkswagen enjoys an excellent reputation worldwide. Although the emissions scandal caused heavy burdens and bad press at the time, VW remains a brand that stands for quality. In hindsight, the scandal surrounding illegal defeat devices in diesel cars was also good for something: Volkswagen oriented itself toward sustainability early on. This shift in strategy in the wake of the emissions scandal resulted in a high-profile e-car offensive in early 2021: Volkswagen plans to cover large parts of its supply chains and sell one million fully electric vehicles every year by 2025.

    This announcement was well received on the stock market. In some circles, Volkswagen was even referred to as "the new Tesla." While this exclamation shows that the market is prone to euphoria, investors get a lot of substance for their money with VW. Thanks to the strategy shift, there is now also a growth perspective. On a one-year horizon, the share has already gained 100% - but has already corrected again. Investors can stay with Volkswagen, but it is uncertain whether the stock will soon make substantial gains.

    Deutsche Bank is back

    The Deutsche Bank share has also made good gains over the past year - the share price has risen by more than 70%. Recently, the German bankers impressed with a profit. Especially in investment banking, things are going well again. Added to this is the interest rate fantasy triggered by inflation fears. If interest rates rise again, banks benefit and can skim off more margin in their traditional lending business.

    Anyone investing in Deutsche Bank shares today speculates that the Frankfurt-based Company will successfully master the structural change in the financial sector. The successes in investment banking already point in the right direction. If asset prices continue to rise after the pandemic, Deutsche Bank will also be able to cut itself a good slice of the pie. As higher interest rates become more likely again with rising prices, the bread-and-butter business could also pick up again with some delay. In the long term, the share still has potential, but setbacks cannot be ruled out in the short term.

    QMines: The crystal clear commodity bet with good odds

    An exciting investment story is offered by the Australian commodities Company QMines, which was launched today on the Australian stock exchange. The Australians focus on copper and gold, combining two of our time's most exciting investment themes: technological progress, including the mobility revolution and the trend towards rising prices. The combination of precious and industrial metals has also convinced the analysts at RaaS. The experts attest to QMines' competent management, promising projects that are also well integrated into existing infrastructure, and robust market demand for commodities.

    In total, QMines is advancing four gold and copper projects in the Australian state of Queensland. The flagship project is Mt. Chalmers, where resources have been mined sporadically in the past. An initial resource estimate sees an inferred resource of 3.9 million tons with grades of 1.15% copper, 0.81% g/t gold and 8.4 g/t silver. However, the Company itself emphasizes enormous exploration potential and plans to drill between 32 and 62,000 meters over the next two years.

    Even though QMines is still in the early stages, the Australian Company's stock offers a crystal-clear scenario. If it succeeds in expanding the existing resources and advancing the project, the stock can benefit from both the fantasy surrounding copper and the demand for gold. With a market capitalization of around EUR 20 million, QMines is a small-cap with room for growth. Although the stock is much more speculative than VW or Deutsche Bank, good news from the upcoming drilling program can also provide the value much more momentum than is the case with established blue chips. For those who like speculative stocks, QMines is a stock whose trend is still at the beginning.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read